Form 8-K - Current report:
SEC Accession No. 0001437749-23-017914
Filing Date
2023-06-21
Accepted
2023-06-21 08:16:21
Documents
16
Period of Report
2023-06-21
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K dmtp20230620_8k.htm   iXBRL 8-K 33981
2 EXHIBIT 99.1 ex_535201.htm EX-99.1 14565
7 dialogo.jpg GRAPHIC 8555
8 remlogo.jpg GRAPHIC 5008
  Complete submission text file 0001437749-23-017914.txt   207636

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA dmac-20230621.xsd EX-101.SCH 3593
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE dmac-20230621_def.xml EX-101.DEF 11409
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE dmac-20230621_lab.xml EX-101.LAB 15280
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE dmac-20230621_pre.xml EX-101.PRE 11569
10 EXTRACTED XBRL INSTANCE DOCUMENT dmtp20230620_8k_htm.xml XML 2583
Mailing Address 301 CARLSON PARKWAY SUITE 210 MINNEAPOLIS MN 55305
Business Address 301 CARLSON PARKWAY SUITE 210 MINNEAPOLIS MN 55305 (763) 496-5454
DiaMedica Therapeutics Inc. (Filer) CIK: 0001401040 (see all company filings)

EIN.: 000000000 | State of Incorp.: Z4 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36291 | Film No.: 231027440
SIC: 2834 Pharmaceutical Preparations